Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 152Recruiting 49Unknown 40Terminated 38Active not recruiting 18Withdrawn 14Not yet recruiting 8Suspended 3No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 17Neoplasms 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Mesothelioma 4Prostatic Neoplasms 3Ovarian Neoplasms 3Mesothelioma, Malignant 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2NSCLC 2Melanoma 2Endometrial Neoplasms 2Diabetes Mellitus 2Carcinoma, Transitional Cell 2Vulvar Neoplasms 1Uterine Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Psoriasis 1Post-Lyme Disease Syndrome 1Pneumonia 1Parkinson Disease 1Pancreatic Neoplasms 1Osteosarcoma 1Obsessive-Compulsive Disorder 1Neoplasms, Squamous Cell 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × Mesothelioma, Malignant × Thoracic × Clear all
NCT05337735 2026-05-04

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

M.D. Anderson Cancer Center

Phase 2 Suspended
140 enrolled
EndocrineGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Hodgkin Disease, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05960773 2026-05-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Suspended
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT01627795 2018-04-18

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Oshadi Drug Administration

Phase 1/2 Suspended
17 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡